SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: trustmanic who wrote ()5/27/1997 11:55:00 AM
From: Mike Leonard   of 1185
 
RSD921 clinical trial report received

Nortran Pharmaceuticals Inc NRT
Shares issued 15,478,503 May 26 close $1.08
Tue 27 May 97 News Release
Ms Sue Milne reports
The company has received a report from the principal investigator on its
phase I clinical trial of RSD921.
The primary objective of this open label, ascending dose trial was to
evaluate the safety of RSD921 in healthy human male volunteers, given by
intravenous infusion. A total of 54 administrations of the drug candidate
was made over a period of about three months.
RSD921 was shown to be well tolerated in humans. There was no evidence of
drug-related adverse events over the dose range tested.
RSD921 is a candidate local anaesthetic and antiarrhythmic drug. Nortran is
seeking to licence RSD921, and is negotiating with potential licencing and
development partners.
(c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News